[301 cases with bronchial asthma treated by kahusu]

Area of Science:

• Immunology
• Pharmacology
• Respiratory Medicine

Context:

• Bronchial asthma (BA) is a chronic respiratory condition characterized by airway inflammation.
• Current treatments aim to manage symptoms and reduce exacerbations.
• Investigating novel therapeutic approaches to enhance immune response and reduce inflammation in BA is crucial.

Purpose:

• To evaluate the therapeutic efficacy and immunomodulatory effects of kahusu compared to heat-killed BCG in patients with bronchial asthma.
• To assess the long-term effectiveness and safety of kahusu in managing BA.

Summary:

• A study compared kahusu (heat-killed BCG and huercaosu) with heat-killed BCG alone in 301 and 30 BA patients, respectively, over a 3-month treatment course, followed by 2 years of observation.
• After 1 and 2 years, effective rates were similar between groups (81.40% vs. 80% at 1 year; 44.83% vs. 42.31% at 2 years), with no statistical significance.
• Laboratory findings indicated strengthened cellular and humoral immunity (increased IgG, IgA; enhanced PHA, OT tests) and reduced inflammation (lowered C3) with kahusu, with no observed side effects.

Impact:

• Kahusu demonstrates potential as an immunomodulatory agent for bronchial asthma, comparable in efficacy to existing treatments.
• The findings suggest that kahusu can enhance immune function and resolve inflammation in BA patients safely.
• Further research may explore optimizing kahusu dosage and its application in different BA phenotypes.